Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00IDR
|
|||
| Former ID |
DIB007096
|
|||
| Drug Name |
Phenylalanine hydroxylase
|
|||
| Synonyms |
Oralase; Phenylase; AvPAL-PEG; Phenylalanine hydroxylase, BioMarin; Phenylalanine hydroxylase, IBEX; Poly ethylene glycol-phenylalanine ammonia lyase; Phenylketonuria therapy (enzyme), BioMarin
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| Company |
Biomarin pharmaceutical
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phenylalanine hydroxylase (PAH) | Target Info | Modulator | [2] |
| BioCyc | Phenylalanine degradation/tyrosine biosynthesis | |||
| KEGG Pathway | Phenylalanine metabolism | |||
| Phenylalanine, tyrosine and tryptophan biosynthesis | ||||
| Metabolic pathways | ||||
| Biosynthesis of amino acids | ||||
| Pathwhiz Pathway | Phenylalanine and Tyrosine Metabolism | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Biogenic Amine Synthesis | ||||
| Metabolism of amino acids and derivatives | ||||
| Abnormal metabolism in phenylketonuria | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00925054) Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU. U.S. National Institutes of Health. | |||
| REF 2 | Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014 Jul 5;384(9937):37-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.